AngioDynamics: Operational Outperformance, Raised FY2026 Outlook, and Advancing Clinical Pipeline Support Buy Rating and $16 Target

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on AngioDynamics, with a price target of $16.00.

Yi Chen has given his Buy rating due to a combination of factors that highlight AngioDynamics’ improving fundamentals and growth outlook. The company delivered stronger-than-expected fiscal 2Q26 results, with both revenue and earnings surpassing prior estimates, driven particularly by robust expansion in its Med Tech segment, including solid contributions from Auryon, AlphaVac, and NanoKnife product lines. Management responded to this momentum by raising full-year FY2026 guidance for revenue and adjusted EBITDA, while reiterating healthy gross margin expectations and projecting positive free cash flow for the year. These trends suggest a strengthening business profile with continued organic growth led by higher-margin Med Tech products.
In addition, Yi Chen views the company’s clinical and regulatory progress as an important value driver for the stock. The FDA’s approval of the APEX-Return pivotal study for the AlphaReturn Blood Management System, used with AlphaVac F18 in acute pulmonary embolism, supports AngioDynamics’ strategy to address procedural needs such as blood conservation and potentially expand its market presence in thrombectomy. The newly approved PAVE pilot study, together with the FDA Breakthrough Device designation for the AngioVac System in right-sided infective endocarditis, underscores the innovation potential and differentiation of its portfolio in complex cardiac and vascular interventions. Taken together, the operational outperformance, raised outlook, and advancing clinical pipeline underpin Yi Chen’s confidence in AngioDynamics’ upside potential and justify maintaining a Buy rating and a $16 price target.

In another report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $18.00 price target.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANGO in relation to earlier this year.